AMGA applauds the decision to not implement Part B drug proposal

AMGA applauded the Centers for Medicare & Medicaid Services’ (CMS’) decision to not move forward with the Medicare Part B Drug Demonstration.

In May, AMGA submitted comments to CMS outlining concerns that the proposal could hinder beneficiary access to needed medications while doing little to improve quality.

“AMGA appreciates that the administration considered stakeholder feedback from AMGA and others and will not move forward with this proposal,” said Donald W. Fisher, Ph.D . . .

To continue reading this article…

Start your monthly or annual subscription to HIT Leaders & News today!

A monthly Standard subscription to all our regular news articles costs only $12.00 per month, or $144.00 for an annual Standard subscription.

Already a subscriber? Log in

 

AMGA, Centers for Medicare & Medicaid Services, CMS, Government Perspectives, Medicare Part B Drug Demonstration

Social

Please follow and ‘Like’ us

facebook
LinkedIn
twitter

©2021 HIT Leaders and News, a GO Digital Media publication. All rights reserved.